Yew Tree Derivative Shows Promise in Cancer Therapy

Yew Tree Derivative Shows Promise in Cancer Therapy

MILAN--Indena announced results of threepreclinical studies involving its IDN 5390, a molecule derived from the yewtree, at a symposium on Molecular Targets and Cancer Therapeutics, held inFrankfurt Nov. 19 to 22. The latest in vivo and in vitro research presented byIndena (www.indena.com) indicated that IDN5390 combined with paclitaxel (a chemotherapy drug also derived from the yewtree) increased the efficacy of the pharmaceutical without increasing toxicity,allowing for a lower, less toxic dose of paclitaxel over a longer treatmentperiod.